Anti-VEGFs as a Treatment for Diabetic Retinopathy and PANORAMA Results
July 29th 2019W. Lloyd Clark, MD, of Palmetto Retina Center, discusses clinical implications of the 52-week PANORAMA results, which found treatment with intravitreal aflibercept injections could reverse disease progression in patients with moderately severe to severe NPDR.
DRIL Presence Predictive of VA Improvement in Patients with Macular Edema, RVO
Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”